{"filings":[{"id":1315159,"accession_number":"0001493152-26-030408","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2026-06-29T11:05:56+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tonix enrolls first patient in Phase 2 MDD study of TNX-102 SL (TONMYA)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient enrolled in HORIZON, a potentially pivotal Phase 2 study of TNX-102 SL 5.6 mg as first-line monotherapy for major depressive disorder.","Primary endpoint: change from baseline in MADRS total score at Week 6; about 360 patients at ~30 US sites.","TNX-102 SL (TONMYA) was FDA approved for fibromyalgia in August 2025; MDD indication is investigational.","CEO notes TNX-102 SL targets poor sleep quality; prior signals in PTSD and fibromyalgia studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":900160,"accession_number":"0001493152-26-027621","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2026-06-08T11:05:29+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tonix secures second GPO agreement for TONMYA, expanding commercial coverage to ~52M lives","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second GPO agreement effective June 1, 2026 adds ~17M US commercial lives (~10% of total).","Total commercial coverage now ~52M lives (~29% of US commercial lives); first GPO covered ~35M from May 1.","TONMYA covered under Medicaid in most states (~75M beneficiaries); Medicare discussions ongoing.","TONMYA (cyclobenzaprine HCl sublingual tablets) approved by FDA Aug 2025 as first new fibromyalgia treatment in over 15 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":677316,"accession_number":"0001493152-26-025324","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2026-05-27T11:05:55+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tonix publishes Phase 1 data for TNX-1500; shows TDAR blockade, favorable safety","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TNX-1500 Phase 1 data in Journal of Clinical Immunology; blocked primary TDAR at all doses (3,10,30 mg/kg).","Secondary TDAR blocked at 10 and 30 mg/kg; peak secondary reduced ~70% vs placebo at 3 mg/kg.","No serious adverse events; mild aphthous ulcers in 3 participants; half-life supports monthly IV dosing.","Phase 2 investigator-initiated kidney transplant study at MGH expected to start 2H 2026 pending FDA IND clearance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":454236,"accession_number":"0001999371-26-010790","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2026-05-15T13:25:40+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tonix reports Phase 1 PK data for TNX-4800 Lyme antibody; two-dose regimen supports 6-month protection","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TNX-4800 Phase 1 PK data presented at Global Lyme Alliance; two-dose 350 mg SC regimen (Day 1, Day 56) modeled.","Simulations predict days above MEC: 10 µg/mL (196 days), 15 µg/mL (161 days), 20 µg/mL (136 days), 5 µg/mL (265 days).","Data supports maintaining serum level above 10 µg/mL for six months after initial dose, proposed Phase 2 primary endpoint.","Adaptive Phase 2 field study planned for first half of 2027, pending FDA agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":15361,"accession_number":"0001999371-26-010487","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2026-05-11T21:17:22+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tonix Q1 net loss $40.2M; TONMYA launch generates $3.7M revenue with 2,145 prescribers","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $6.9M (TONMYA $3.7M, legacy products $3.2M); net loss $40.2M ($2.93/share).","Cash $185.5M at Mar 31; raised $22.6M post-quarter via ATM; runway into early Q2 2027.","TONMYA Q1: 2,145 HCPs prescribed, 3,588 patients initiated, ~5,400 Rx; cumulative 11,016 Rx through May 1.","Secured GPO agreement covering ~35M commercial lives; Medicaid coverage in 38 states (~55M lives).","TNX-4800 Phase 2 Lyme prevention study planned for 2027; TNX-102 SL MDD Phase 2 to start mid-2026."],"consensus_eps_estimate":-2.482,"consensus_eps_actual":-2.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":6878000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92819,"accession_number":"0001999371-26-010226","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Tonix shareholders approve reverse stock split authorization and 2026 equity plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split authorized up to 1:250 ratio; 4,400,765 votes for, 2,826,586 against.","2026 Stock Incentive Plan approved; 2,019,646 for, 1,624,412 against, 3,504,257 broker non-votes.","PricewaterhouseCoopers LLP ratified as independent auditor for FY2026; 6,910,516 votes for.","Nine directors re-elected including CEO Seth Lederman; all nominees received >84% of votes cast.","Shareholder turnout 54.22% (7,267,759 shares of 13.4M outstanding) on record date March 19, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92818,"accession_number":"0001999371-26-010039","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tonix secures GPO coverage for TONMYA, expanding commercial access to ~35M patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement effective May 1, 2026 with leading GPO provides coverage for ~35M U.S. commercial lives (20% of ~177M total).","TONMYA is the first new FDA-approved fibromyalgia treatment in over 15 years; commercially launched November 2025.","TONMYA now covered under Medicaid in 38 states, representing ~55M beneficiaries (73% of ~75M Medicaid lives).","Coverage includes standard utilization management criteria; patient savings program available for eligible commercially insured.","CEO Seth Lederman emphasizes continued pursuit of additional commercial and government channel coverage."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92817,"accession_number":"0001999371-26-009744","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"Tonix reports preliminary Q1 net loss $40.8M, cash $185.5M, revenue $6.9M","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Net loss for Q1 2026 was ~$40.8M, up from $16.8M in Q1 2025; revenue rose to $6.9M from $2.4M, led by TONMYA ($3.7M).","Cash and equivalents at March 31, 2026: $185.5M; common shares outstanding as of April 30, 2026: 15,540,801.","Net cash used in operations was $40.2M in Q1 2026 vs $16.6M in Q1 2025; capex was $1.7M vs $6,000.","Raised $17.4M net from equity offerings in Q2 2026; cash runway expected into Q2 2027.","Preliminary results subject to revision; final Q1 2026 10-Q expected on or about May 11, 2026."],"consensus_eps_estimate":-2.482,"consensus_eps_actual":-2.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":6878000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92816,"accession_number":"0001999371-26-009289","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tonix presents TNX-4800 Phase 1 data; plans adaptive Phase 2 field study for Lyme disease prevention in H1 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 data of TNX-4800 (anti-OspA mAb) for Lyme disease presented at Ticks and Tickborne Diseases Symposium.","Planned adaptive Phase 2 field study: two-dose SC regimen, primary endpoint 6-month protection; start H1 2027 pending FDA agreement.","FDA Type C meeting scheduled early Q3 2026 to discuss Phase 2 study design.","Each fixed subcutaneous dose expected to provide exposure comparable to 5 mg/kg dose in Phase 1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92815,"accession_number":"0001999371-26-008771","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tonix reports preclinical data for TNX-1700 and TNX-4700 at AACR 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TNX-1700 reversed aging-associated gastric inflammation and attenuated tumor progression in aged mouse model.","TNX-1700 showed dose-independent linear PK in non-human primates and transgenic mice; no significant weight loss.","TNX-4700 anti-BTLA mAbs demonstrated potent, high-affinity binding and functional antagonism in vitro.","Three TNX-4700 antagonists had reduced FcgRI binding and no FcgRIIB binding, potentially lowering FcR-dependent toxicities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103970,"accession_number":"0001999371-26-007254","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tonix reports Phase 1 data for Lyme prophylactic TNX-4800; Phase 2 field study planned for H1 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 data (N=44) showed no significant safety signals; mean half-life 62-69 days; serum levels at 5 mg/kg ~10 μg/ml at 4 months, ~2x in vitro MEC.","Planned Phase 2 field study: randomized, double-blind, placebo-controlled, 350 mg SC single dose; primary endpoint Lyme prevention at 4 months.","Phase 2 expected to initiate in H1 2027 pending FDA clearance; GMP product available early 2027.","TNX-4800 is a long-acting anti-OspA monoclonal antibody in-licensed from UMass Chan in 2025; no FDA-approved Lyme vaccine/prophylactic in US.","If needed, controlled human infection model study planned for 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103969,"accession_number":"0001999371-26-006915","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tonix doses first participant in Phase 1 study of TNX-1900 for migraine and craniofacial pain","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First participant dosed in Phase 1 investigator-initiated study of TNX-1900 (intranasal potentiated oxytocin).","Study evaluates effect on trigeminal nerve-mediated vasodilation using capsaicin and electrical stimulation in healthy female volunteers.","Principal investigator Dr. Antoinette Maassen van den Brink, Erasmus University Medical Center.","TNX-1900 targets a distinct pathway from CGRP inhibitors and triptans, blocking CGRP release in animal models.","Use of Laser Speckle Contrast Imaging (LSCI) for real-time dermal blood flow measurements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103968,"accession_number":"0001999371-26-006169","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2026-03-18T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Tonix Pharmaceuticals dismisses EisnerAmper, appoints PwC as new auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed EisnerAmper on March 16, 2026; no disagreements on accounting principles or practices.","Audit reports for FY2024 and FY2025 had going-concern paragraph due to losses and negative cash flows.","Prior material weaknesses (complex transactions, inventory, warrants) were remediated by end of 2024; no restatements.","Appointed PricewaterhouseCoopers LLP as independent auditor for FY2026, effective March 16, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103967,"accession_number":"0001999371-26-005742","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tonix reports Q4 2025 net loss $46.9M; TONMYA launch shows ~4,200 prescriptions","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss available to common stockholders for Q4 2025 was $46.9M ($3.98/share) vs $22.1M ($9.77/share) in Q4 2024.","Full year 2025 net product revenue $13.1M, including TONMYA launch from Nov 17–Dec 31: $1.4M.","TONMYA launch-to-date (Nov 17,2025–Feb 27,2026): >1,500 HCPs prescribed, ~2,500 patients initiated, ~4,200 cumulative prescriptions.","Cash and equivalents $207.6M as of Dec 31, 2025 (up from $98.8M); subsequent ATM raised $8.6M.","Cash runway expected into Q1 2027; shares outstanding 13.4M as of March 11, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103966,"accession_number":"0001999371-26-005466","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tonix unveils post hoc data: TONMYA pain relief from Day 2; NNT=7, NNH=26","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Post hoc analysis of Phase 3 RESILIENT trial (n=457) shows TONMYA pain improvement vs placebo from Day 2, significant through Week 14 (p<0.001).","Primary endpoint met with LS mean treatment difference of -0.65 in weekly pain score; all key secondary endpoints significant.","Pooled analysis (n=959) reports NNT for ≥30% pain reduction at Week 14 = 7 (95% CI 5-12); NNH for discontinuation = 26 (95% CI 14-110).","LHH = 3.7, indicating nearly 4-fold greater likelihood of clinical benefit vs adverse event-related discontinuation.","TONMYA launched in November 2025 as first fibromyalgia approval in 15 years; mild transient oral hypoesthesia and dysgeusia most common adverse events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103965,"accession_number":"0001999371-26-004897","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tonix Pharmaceuticals uplists from Nasdaq Capital Market to Global Select Market","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Nasdaq approved transfer of TNXP common stock, effective March 3, 2026, ticker unchanged.","Uplisting reflects compliance with higher financial and corporate governance standards.","CEO Seth Lederman noted uplisting may enhance visibility, liquidity, and institutional access."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103964,"accession_number":"0001999371-26-002429","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"Tonix prelim 2025: net loss $118.9M vs $130.0M; cash $207.6M funds ops into Q1 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash & equivalents $207.6M at Dec 31, 2025; 12.79M shares outstanding as of Jan 30, 2026.","Net loss $118.9M (2025) vs $130.0M (2024); net cash used in operations $99.0M vs $60.9M.","Net product revenue $13.1M (2025) vs $10.1M (2024); Zembrace/Tosymra $11.7M vs $10.1M.","TONMYA launch Nov 17, 2025 generated $1.4M from launch to Dec 31, 2025.","Capital expenditures $3.4M in 2025 vs $0.1M in 2024; cash expected to fund ops into Q1 2027."],"consensus_eps_estimate":-3.2538,"consensus_eps_actual":-14.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":13107000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120246,"accession_number":"0001999371-25-021283","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Tonix Pharmaceuticals prices $20M registered direct offering with Point72; shares and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 615,025 shares at $16.26 and pre-funded warrants for 615,025 shares at $16.259 to Point72; gross proceeds ~$20M.","Closing expected Dec 30, 2025; TD Cowen sole placement agent.","Net proceeds to fund commercialization, pipeline development, and working capital.","30-day lock-up on additional equity issuance; 180-day ban on variable rate transactions.","Directors and officers also subject to 30-day lock-up."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120245,"accession_number":"0001999371-25-021194","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tonix announces TNX-4800 Phase 1 data, plans 2026 FDA meeting for Phase 2/3 Lyme disease prevention","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 study of TNX-4800 in 44 subjects showed mean half-life of 62-69 days; detectable up to 12 months.","Company will meet with FDA in 2026 to explore Phase 2/3 development options including a controlled human infection model (CHIM).","Expects GMP investigational product available for clinical testing in early 2027.","TNX-4800 targets OspA of Borrelia burgdorferi; designed as annual seasonal prophylaxis for Lyme disease.","Anti-drug antibodies in <10% of subjects with no impact on PK; most adverse events mild or moderate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120244,"accession_number":"0001999371-25-020361","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tonix licenses exclusive worldwide rights to TNX-4900 for neuropathic pain from Rutgers University","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Licensed exclusive worldwide rights to TNX-4900 (S1R antagonist) from Rutgers University for chronic neuropathic pain.","TNX-4900: Ki=7.5 nM, >100-fold selectivity over Sigma-2, oral bioavailability ~28%.","Preclinical efficacy in diabetic and chemotherapy-induced neuropathic pain models without tolerance or motor impairment.","Company plans IND-enabling studies; no financial terms disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120243,"accession_number":"0001999371-25-019833","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2025-12-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tonix Pharmaceuticals appoints Irina Ishak as General Counsel effective Dec 8, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Irina Ishak joins from Lowenstein Sandler LLP where she was Senior Counsel since 2013.","She previously advised Tonix since 2017 on financings, licensing, and corporate governance.","Ms. Ishak brings over 25 years of legal experience in life sciences, including at Savient Pharmaceuticals.","Tonix recently launched TONMYA for fibromyalgia, first new FDA-approved treatment in over 15 years.","Seth Lederman, CEO, highlights her expertise in complex transactions and public company matters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120242,"accession_number":"0001999371-25-018430","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2025-11-24T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tonix Pharma receives FDA IND clearance for TNX-102 SL Phase 2 MDD study","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for TNX-102 SL (cyclobenzaprine HCl) 5.6 mg sublingual tablets to treat major depressive disorder in adults.","Potentially pivotal Phase 2 HORIZON study: 6-week, randomized, double-blind, placebo-controlled, 360 patients at ~30 U.S. sites.","Primary endpoint: MADRS total score change from baseline at Week 6; enrollment to begin mid-2026.","TNX-102 SL targets disrupted sleep associated with MDD; prior fibromyalgia and PTSD studies showed depression symptom improvements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120241,"accession_number":"0001999371-25-018392","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Tonix Pharmaceuticals increases ATM equity offering capacity from $150M to $400M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sales Agreement with A.G.P./Alliance Global Partners amended to raise maximum aggregate offering price to $400M from $150M.","Amendment dated November 21, 2025; shares to be sold through at-the-market (ATM) issuance.","Company filed legal opinion from Brownstein Hyatt Farber Schreck on share legality.","Fundraising capacity more than doubled; no stated use of proceeds in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120240,"accession_number":"0001999371-25-018108","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Tonix Pharma expands share repurchase program by $25M to $35M total authorized","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved an additional $25.0 million for share repurchases, raising total authorized to $35.0 million.","Repurchases may occur from time to time in open-market or private transactions depending on conditions.","The original $10 million authorization was increased; no expiration date or commitment to repurchase any specific number of shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120239,"accession_number":"0001999371-25-017964","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tonix launches TONMYA as first new fibromyalgia treatment in 15 years","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TONMYA (cyclobenzaprine HCl sublingual tablets) now available by prescription nationwide.","FDA approved Aug 15, 2025; first non-opioid once-daily bedtime analgesic for fibromyalgia.","Phase 3 trials (nearly 1,000 patients) showed significant pain reduction vs placebo at 14 weeks.","Most common side effects: oral hypoesthesia, somnolence, dry mouth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120238,"accession_number":"0001999371-25-017369","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tonix Q3 2025 net loss widens to $32M; cash $190.1M; Tonmya launch in November","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $3.3M (up from $2.8M YoY) from Zembrace/Tosymra sales.","Net loss $32.0M ($3.59 per share) vs $14.2M ($22.68 per share) in Q3 2024; SG&A surged to $25.7M on Tonmya launch prep.","Cash and equivalents $190.1M (Dec 2024: $98.8M); cash runway into Q1 2027 including $34.7M from Q4 2025 equity offerings.","Tonmya (fibromyalgia) launch in November 2025; 90 sales reps in field; WAC established; payer formulary placement for Tosymra in 2026.","Tonix in-licensed TNX-4800 (Lyme disease mAb) and announced Phase 2 collaboration for TNX-1500 (kidney transplant)."],"consensus_eps_estimate":-3.6567,"consensus_eps_actual":-10.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":7717000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120237,"accession_number":"0001999371-25-016108","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"Tonix reports preliminary Q3 net loss $32M, plans Tonmya launch by Nov 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary Q3 2025 net loss ~$32.0M vs $14.2M YoY; net revenue $3.3M vs $2.8M.","Cash and equivalents ~$190.1M at Sept 30, 2025; net operating cash use $28.8M.","Subsequent equity offerings net $29.3M; cash runway into Q1 2027.","U.S. commercial launch of Tonmya for fibromyalgia expected by end of Nov 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120236,"accession_number":"0001999371-25-015796","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tonix doses first patient in FOCUS study of intranasal oxytocin for AVP-D at MGH","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in FOCUS study at Massachusetts General Hospital for arginine-vasopressin deficiency (AVP-D).","Randomized, double-blind, placebo-controlled crossover pilot evaluating TNX-2900 (6 IU) and TNX-1900 (24 IU).","Primary endpoints: markers of anxiety, depression, and socioemotional functioning; exploratory 2-week replacement on mental health.","Study aims to generate preliminary data for future oxytocin replacement therapy in AVP-D.","TNX-1900/TNX-2900 are intranasal Mg2+-potentiated oxytocin formulations in development for multiple conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120235,"accession_number":"0001999371-25-014776","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tonix Pharmaceuticals plans Phase 2 trial of TNX-102 SL for MDD in 2026, Phase 2/3 of TNX-4800 for Lyme in 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 trial of TNX-102 SL for major depressive disorder expected to start in 2026.","Phase 2/3 study of TNX-4800 for seasonal Lyme disease prevention expected to start in 2027.","TNX-102 SL is currently FDA-approved for fibromyalgia; this expands its potential indication."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136825,"accession_number":"0001999371-25-014216","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tonix sets Tonmya WAC at $1,860/month; appoints Ganesh Kamath as Head of Market Access","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Tonmya (cyclobenzaprine HCl sublingual tablets) approved Aug 15, 2025 for fibromyalgia; launch expected Q4 2025.","Wholesale acquisition cost (WAC) set at $1,860/month for 60-count supply; geriatric/mild hepatic: $930/month for 30-count.","Ganesh Kamath appointed Head of Market Access effective Sept 29, 2025; brings 25+ years experience from Bayer, Hutchmed, CuriaGlobal.","Kamath will lead pricing, contracting, and payer engagement for Tonmya launch and pipeline.","First new fibromyalgia prescription therapy in over 15 years; Tonix also markets two acute migraine treatments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136824,"accession_number":"0001999371-25-014108","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tonix plans Phase 2 trial of TNX-2900 for Prader-Willi syndrome in 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TNX-2900 (intranasal magnesium-potentiated oxytocin) to enter Phase 2 in children ages 8-17.5 with PWS, starting 2026.","FDA cleared IND; Orphan Drug and Rare Pediatric Disease designations; eligible for Priority Review Voucher upon approval.","Phase 2 trial is randomized, double-blind, placebo-controlled; 12-week treatment; 3 dose arms vs placebo (1:1:1:1).","Primary endpoint: change from baseline in Hyperphagia Questionnaire (HQ-CT); secondary: behavior, caregiver burden, quality of life.","PWS affects 1 in 10,000-30,000 births; average life expectancy <30 years due to hyperphagia-driven obesity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136823,"accession_number":"0001999371-25-013498","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tonix completes positive Pre-IND meeting with FDA for TNX-102 SL in MDD; IND filing Q4 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA found proposed long-term safety data collection plan generally reasonable, potentially streamlining development.","Company plans to pursue sNDA to expand TNX-102 SL indication to include MDD.","IND filing for TNX-102 SL in MDD planned for Q4 2025; Phase 2 trial expected shortly after.","TNX-102 SL (sublingual cyclobenzaprine HCl) is already FDA-approved for fibromyalgia as Tonmya.","Decision based on exploratory findings that improving sleep quality may positively impact depressive symptoms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136822,"accession_number":"0001999371-25-013413","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2025-09-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tonix in-licenses Phase 2/3-ready Lyme disease antibody TNX-4800","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["In-licensed worldwide rights to TNX-4800, a fully human monoclonal antibody targeting OspA of Borrelia burgdorferi.","Designed as a single subcutaneous dose each Spring to protect against Lyme disease through Fall tick season.","Positive Phase 1 study showed safety, tolerability, and linear PK/PD/efficacy relationship (1:1:1).","Planning adaptive Phase 2/3 study; ~70 million people in U.S. endemic areas eligible for treatment.","Developed by UMass Chan Medical School; no FDA-approved vaccines currently available for Lyme disease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136821,"accession_number":"0001999371-25-011510","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tonix receives FDA approval of Tonmya (cyclobenzaprine HCl) for fibromyalgia in adults","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved Tonmya (cyclobenzaprine HCl sublingual tablets) for treatment of fibromyalgia in adults.","Product launch and commercialization strategy underway; commercial team led by Thomas Englese.","Webcast and conference call held August 18, 2025 to discuss approval and go-to-market plan.","Management presented on product label, market opportunity, and key clinical data from TNX-102 SL trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136820,"accession_number":"0001999371-25-011478","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA approves Tonix's Tonmya for fibromyalgia; first new therapy in over 15 years","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Tonmya (cyclobenzaprine HCl sublingual tablets) approved for adults with fibromyalgia; Q4 2025 commercial launch expected.","Approval based on two Phase 3 trials (~1,000 patients) showing significant pain reduction vs placebo at 14 weeks.","Over 10 million U.S. adults affected; Tonmya is first-in-class non-opioid bedtime analgesic.","Company to host webcast August 18 at 8:30 AM ET to discuss approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136819,"accession_number":"0001999371-25-011053","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tonix Q2 net loss $28.3M; cash $125.3M; FDA PDUFA Aug 15 for TNX-102 SL","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $2.0M (down from $2.2M YoY); SG&A surged to $16.2M from $7.5M on pre-launch spend.","Cash $125.3M at June 30; plus $51.5M raised in Q3 2025; runway into Q3 2026.","FDA PDUFA date Aug 15, 2025 for TNX-102 SL (fibromyalgia); Fast Track designation.","First patient dosed in DoD-funded OASIS trial of TNX-102 SL for acute stress reaction.","Appointed Joseph Hand as General Counsel and James Hunter to board; added to Russell 2000/3000."],"consensus_eps_estimate":-3.2793,"consensus_eps_actual":-6.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":4427000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136818,"accession_number":"0001999371-25-009884","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2025-07-25T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"Tonix reports preliminary Q2 net operating loss of $26.3M, cash $125.3M, runway to Q3 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net operating loss of $26.3M in Q2 2025, improved from $78.8M in Q2 2024.","Cash and equivalents $125.3M at June 30; additional $50.6M raised in Q3 2025 equity offerings.","Net cash used in ops $16.3M ($9.9M in Q2 2024); capex $1.1M (nil prior year).","Revenue from marketed products $2.0M, down from $2.2M YoY.","Company expects runway into Q3 2026; shares outstanding 8.7M as of July 25."],"consensus_eps_estimate":-3.2793,"consensus_eps_actual":-6.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":4427000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136817,"accession_number":"0001999371-25-009455","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tonix launches 'Move Fibro Forward' awareness campaign for fibromyalgia patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Tonix Medicines subsidiary launched campaign to support individuals with fibromyalgia.","No new FDA-approved treatments for fibromyalgia in over 15 years cited as motivation.","Campaign includes website (movefibroforward.com) and partnerships with patient advocates.","CEO quotes emphasize commitment to fibromyalgia community and patient visibility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136816,"accession_number":"0001999371-25-009199","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tonix plans 70-90 sales reps for TNX-102 SL if FDA approves fibromyalgia NDA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company plans to hire 70-90 sales representatives for TNX-102 SL conditional on FDA approval of NDA for fibromyalgia.","TNX-102 SL NDA is under FDA review; approval decision would trigger commercial launch planning.","Updated corporate presentation filed as Exhibit 99.01 for investor meetings; may contain nonpublic information."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136815,"accession_number":"0001999371-25-008900","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tonix TNX-801 vaccine data: 100,000-fold less virulent, s.c. route protective","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TNX-801 is up to 100,000-fold less virulent than licensed vaccinia in interferon receptor knockout mice.","Subcutaneous administration yields equivalent protection to percutaneous route; company plans s.c. product first.","Single dose protected all vaccinated macaques from lethal Clade I mpox challenge without lesions.","Rabbit models remained fully protected for 14 months post single dose.","Company to advance TNX-801 into clinic via subcutaneous delivery for mpox and smallpox prevention."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136814,"accession_number":"0001999371-25-008877","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tonix Pharmaceuticals Announces Publication of Phase 3 RESILIENT Trial Data for TNX-102 SL","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Full results from confirmatory Phase 3 RESILIENT trial of TNX-102 SL published online in Pain Medicine on July 9, 2025.","TNX-102 SL achieved statistically significant improvement in primary endpoint of reducing fibromyalgia pain vs placebo (LS mean reduction 1.8 vs 1.2 points).","Statistically significant improvements observed across all six prespecified key secondary endpoints.","FDA PDUFA target date for TNX-102 SL is August 15, 2025; if approved, would be first new fibromyalgia drug in over 15 years.","TNX-102 SL was generally well tolerated; most common AEs were mild oral tingling/numbness and aftertaste, no drug-related serious AEs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136813,"accession_number":"0001999371-25-008651","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2025-07-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tonix announces preclinical data for TNX-1700 in gastric cancer models published in Cancer Cell","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["mTNX-1700 plus anti-PD-1 increased survival and decreased metastases in gastric cancer animal models vs anti-PD-1 alone.","Treatment associated with activation of CD8+ T cells and limiting neutrophil-mediated immune evasion.","Human version TNX-1700 (hTFF2-HSA) is in preclinical development for gastric and colorectal cancers.","Collaboration with Columbia University's Medical School; paper titled 'A CXCR4 Partial Agonist, Improves Immunotherapy...'.","Data support further development of TNX-1700 to overcome resistance to anti-PD-1 immunotherapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154061,"accession_number":"0001999371-25-007790","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tonix presents positive Phase 3 TNX-102 SL data at EULAR; PDUFA Aug 15, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TNX-102 SL (sublingual cyclobenzaprine) showed statistically significant pain reduction in Phase 3 RESILIENT study at 14 weeks.","FDA PDUFA goal date for TNX-102 SL is August 15, 2025; if approved, would be first new fibromyalgia drug in >15 years.","Novel mechanism targets non-restorative sleep by acting on four post-synaptic receptors regulating sleep.","Non-opioid analgesic designed for transmucosal delivery to bypass first-pass metabolism and reduce norcyclobenzaprine accumulation.","Data presented at Annual European Congress of Rheumatology (EULAR) 2025 in Barcelona, June 11-14."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154060,"accession_number":"0001999371-25-007734","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Tonix appoints former EVP James Hunter to Board; 7,740 option grant at $34.54","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective June 12, 2025; Hunter served as EVP Commercial from June 2023 to Dec 2024.","Received 7,740 stock options at $34.54, vesting at 2026 annual shareholder meeting.","Hunter led launch of Tonix Medicines and migraine asset acquisitions Zembrace and Tosymra.","Board addition strengthens commercial expertise ahead of potential TNX-102 SL fibromyalgia launch; PDUFA Aug 15, 2025.","Not independent under NASDAQ standards due to prior consulting and employment compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154059,"accession_number":"0001999371-25-007625","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Tonix enters $150M ATM equity facility and $75M Lincoln Park purchase agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM facility with A.G.P. allows sale of up to $150M in common stock at 3% commission.","Lincoln Park Purchase Agreement enables up to $75M in stock sales with 97% of VWAP pricing.","Issued 48,708 commitment shares to Lincoln Park as fee; no upper price limit for purchases.","Lincoln Park purchases capped at 1,470,703 shares (19.99% of outstanding) unless stockholder approval or price ≥$37.74.","Proceeds expected for working capital and general corporate purposes; existing shelf registration utilized."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154058,"accession_number":"0001999371-25-006473","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tonix doses first patient in Phase 2 OASIS trial of TNX-102 SL for acute stress reaction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 OASIS trial evaluating TNX-102 SL in reducing severity of acute stress reaction and frequency of acute stress disorder.","Trial sponsored by UNC Institute for Trauma Recovery with a $3 million grant from the U.S. Department of Defense.","Plans to enroll ~180 motor vehicle collision survivors at U.S. emergency departments; randomized to TNX-102 SL 5.6 mg or placebo for two weeks.","Topline results expected in the second half of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154057,"accession_number":"0001999371-25-006011","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tonix Pharmaceuticals appoints Joseph Hand as General Counsel and EVP of Operations","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joseph Hand appointed General Counsel and EVP of Operations, effective May 14, 2025.","Hand brings over 20 years biopharma experience; served on Celgene's Executive Committee for nearly a decade.","Played key roles in Celgene's $74B acquisition by BMS and $13.4B divestiture of Otezla to Amgen.","Appointment comes as Tonix prepares for potential FDA approval of TNX-102 SL for fibromyalgia by August 15, 2025.","Hand previously served as Chief Administrative Officer at Phathom Pharmaceuticals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154056,"accession_number":"0001999371-25-005877","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tonix Q1 net loss $16.8M; cash $131.7M; PDUFA date Aug 15 for TNX-102 SL","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $16.8M ($2.84/share) vs $14.9M ($535.72/share) in Q1 2024; product revenue $2.4M.","Cash and equivalents $131.7M as of March 31, 2025; cash runway into Q2 2026.","FDA PDUFA goal date Aug 15, 2025 for TNX-102 SL for fibromyalgia; if approved, first new drug in >15 years.","Positive Phase 1 results for TNX-1500 anti-CD40L mAb; plans for Phase 2 in kidney transplant.","Discontinued Phase 2 CATALYST study of TNX-1300 due to slow enrollment; not safety/efficacy."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":2429000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154055,"accession_number":"0001999371-25-005717","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Tonix shareholders approve reverse stock split authorization and stock plan amendments at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split authorized at ratio between 1:2 and 1:250, with 1,764,316 for, 1,203,561 against.","Stock incentive plan amended to increase shares by 1,000,000; 751,420 votes for, 724,627 against.","2025 Employee Stock Purchase Plan approved with 1,134,671 votes for, 249,372 against.","Say-on-pay proposal approved with 1,045,066 votes for; frequency set to every three years.","All 8 director nominees elected; auditor EisnerAmper LLP ratified with 2,812,075 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154054,"accession_number":"0001999371-25-004974","cik":1430306,"company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tonix Pharmaceuticals Presents Positive Preclinical Data on TNX-1700 for Gastric Cancer at AACR 2025","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["At AACR 2025, Tonix showed TFF2-MSA (murine TNX-1700) plus anti-PD1 inhibited gastric tumor growth by 78.29% in mouse models.","Combination therapy activated cancer-killing CD8+ T cells and reduced immunosuppressive PMN-MDSCs in the tumor microenvironment.","TNX-1700 (hTFF2-HAS) is in preclinical development for gastric and colorectal cancers, with further studies planned.","Data demonstrated TFF2-MSA outperformed CXCR4 antagonist AMD3100 in reducing PMN-MDSC generation.","TFF2 reduction correlated with elevated PMN-MDSCs in gastric cancer patients, supporting the therapeutic target."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":201890234.08477363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2025-04-29T23:59:59+00:00|154054"}